Phocas Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-819,476
Closed -$14.2M – 12
2026
Q2
$14.2M Sell
819,476
-183,188
-18% -$2.51M 1.97% 2
2026
Q1
$12.5M Sell
1,002,664
-280,310
-22% -$3.76M 1.96% 1
2025
Q4
$16.2M Sell
1,282,974
-2,810
-0.2% -$32.2K 2.1% 2
2025
Q3
$12.9M Buy
1,285,784
+26,220
+2% +$235K 1.67% 8
2025
Q2
$10.2M Buy
1,259,564
+186
+0% +$1.4K 1.47% 15
2025
Q1
$10.6M Sell
1,259,378
-71,035
-5% -$593K 1.62% 9
2024
Q4
$10.5M Buy
+1,330,413
New +$11.2M 1.41% 16
2023
Q4
$4.34M Buy
+714,890
New +$3.18M 0.57% 82
2019
Q2
– Sell
-376,213
Closed -$5.33M – 323
2019
Q1
$5.33M Buy
+376,213
New +$4.97M 0.54% 83

Other funds holding AMRX

Phocas Financial's AMRX Position: Q3 2026 in Review

Phocas Financial sold out of Amneal Pharmaceuticals (AMRX) in Q3 2026, closing a stake of 819,476 shares — an estimated $14.2M sold.

Phocas Financial first reported a position in AMRX in Q1 2019 and held it in 9 quarters. The position peaked at $16.2M in Q4 2025. 264 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • Phocas Financial reported no remaining Amneal Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Phocas Financial sold 819,476 Amneal Pharmaceuticals shares in Q3 2026, an estimated $14.2M.
  • Phocas Financial first reported a position in Amneal Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Phocas Financial's Amneal Pharmaceuticals position peaked at $16.2M in Q4 2025.
  • 264 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Phocas Financial's 13F filing for Q3 2026.